Drug Profile
Vibecotamab - Xencor
Alternative Names: CD123 x CD3 - Xencor; SQZ 622; XmAb 14045Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Xencor
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia
Most Recent Events
- 28 Dec 2021 Phase I trial is still ongoing for Acute myeloid leukaemia (Second-line therapy or greater) in USA (NCT02730312)
- 09 Nov 2021 Discontinued - Phase-I for Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV)
- 30 Sep 2021 Xencor completes a Phase-I trial in Acute myeloid leukemia (Second-line therapy or greater) in USA (IV) (NCT02730312)